Literature DB >> 3857768

Underlying medical conditions in young patients and ethnic differences in retinal vein occlusion.

P M Dodson, E E Kritzinger.   

Abstract

Eighty-seven patients with retinal vein occlusion were investigated for the prevalence of associated conditions, and divided in two groups, young (less than 50 years, n = 40) and an older group (greater than 50 years, n = 47). Young patients had a highly significant decreased prevalence of hypertension compared to the older group (27 per cent versus 62 per cent: P less than 0.001), with hyperlipidaemia being the predominant underlying condition (35 per cent). Four young female patients presenting with retinal vein occlusion were on the contraceptive pill. In the majority of young patients (60 per cent) an underlying medical condition could be identified. Striking ethnic differences in the occurrence of retinal vein occlusion have also been observed in a total of 214 patients referred without prior selection in two major ophthalmological centres over a four year period. Only 3 per cent of patients with retinal vein occlusion were Asian and 2 per cent of West Indian origin. In particular, no West Indian patient has been seen with the central form of venous occlusion. We conclude that hyperlipidaemia, and not hypertension, is the predominant associated medical condition in young patients and that other aetiological factors including the contraceptive pill may be found. Marked ethnic differences have also been observed which may give further insight into the exact aetiology of retinal vein occlusion.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3857768

Source DB:  PubMed          Journal:  Trans Ophthalmol Soc U K        ISSN: 0078-5334


  10 in total

1.  Efficacy of intravitreal triamcinolone for macular oedema due to CRVO after anti-androgen therapy for hirsutism in a young monocular female.

Authors:  Hassan Al-Dhibi; Imtiaz A Chaudhry; Annoud Al-Saati; Farrukh A Shamsi
Journal:  Br J Ophthalmol       Date:  2007-11       Impact factor: 4.638

Review 2.  Central retinal vein occlusion: what's the story?

Authors:  T H Williamson
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

3.  Medical conditions underlying retinal vein occlusion in patients with glaucoma or ocular hypertension.

Authors:  M D Cole; P M Dodson; S Hendeles
Journal:  Br J Ophthalmol       Date:  1989-09       Impact factor: 4.638

Review 4.  Retinal vein occlusions: a review for the internist.

Authors:  Rossella Marcucci; Francesco Sofi; Elisa Grifoni; Andrea Sodi; Domenico Prisco
Journal:  Intern Emerg Med       Date:  2010-12-14       Impact factor: 3.397

5.  Central retinal vein occlusion in a young Chinese population: risk factors and associated morbidity and mortality.

Authors:  Jane Zea-Chin Kuo; Chi-Chun Lai; Frank Shih-Chang Ong; Chia-Pang Shih; Ling Yeung; Tun-Lu Chen; Kuan-Jen Chen; Wei-Chi Wu
Journal:  Retina       Date:  2010-03       Impact factor: 4.256

6.  Medical conditions underlying recurrence of retinal vein occlusion.

Authors:  P M Dodson; A J Kubicki; K G Taylor; E E Kritzinger
Journal:  Br J Ophthalmol       Date:  1985-07       Impact factor: 4.638

7.  Central retinal vein occlusion in young people.

Authors:  G Giuffrè; G Randazzo-Papa; C Palumbo
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

8.  Central retinal vein occlusion in people aged 40 years or less: a review of 17 patients.

Authors:  R F Walters; D J Spalton
Journal:  Br J Ophthalmol       Date:  1990-01       Impact factor: 4.638

Review 9.  Guidance for the management of venous thrombosis in unusual sites.

Authors:  Walter Ageno; Jan Beyer-Westendorf; David A Garcia; Alejandro Lazo-Langner; Robert D McBane; Maurizio Paciaroni
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

10.  Central Retinal Vein Occlusion in Younger Swedish Adults: Case Reports and Review of the Literature.

Authors:  Elisabeth Wittström
Journal:  Open Ophthalmol J       Date:  2017-05-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.